Medtronic Upgraded to Neutral by Goldman Sachs Following Strong Q2 Results, Sets $111 Price Target
AI Summary1 min read
TL;DR
Goldman Sachs upgraded Medtronic to Neutral after strong Q2 results and R&D investments, setting a $111 price target despite below-average valuation.
Tags
Medtronic
Goldman Sachs upgrades Medtronic (MDT) to Neutral due to strong Q2 FY26 results and increased R&D investments. Despite valuation being below industry average, Goldman set a 12-month price target of $111. Medtronic's strategic focus on sustainable growth through enhanced R&D and SG&A investments.
